Increasing Whole Grain Intake as Part of Prevention and Treatment of Nonalcoholic Fatty Liver Disease by Alastair B. Ross, Jean-Philippe Godin, Kaori Minehira, John P. Kirwan

“…Due to their nutrient and phytochemical composition, switching from consuming mainly refined grains to whole grains should be considered as part of the nutritional guidelines for patients diagnosed with or at risk for fatty liver disease.…”
Get full text

The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review by Seyedeh Alia Moosavian, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar

“…Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that can lead to end-stage liver disease needing a liver transplant. …”
Get full text

Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease by Kadir Ozturk, Omer Kurt, Tolga Dogan, Alptug Ozen, Hakan Demirci, Fatih Yesildal, Murat Kantarcioglu, Turker Turker, Ahmet Kerem Guler, Yıldırım Karslioglu, Battal Altun, Ahmet Uygun, Sait Bagci

Get full text

Long-Term Effects of Metformin and Lifestyle Modification on Nonalcoholic Fatty Liver Disease Obese Adolescents by Lian Tock, Ana R. Dâmaso, Aline de Piano, June Carnier, Priscila L. Sanches, Henrique Manoel Lederman, Regina M. Y. Ernandes, Marco Túlio de Mello, Sérgio Tufik

Get full text

Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study by Steven Dooley, Juan Du, Xiaoping Tang, Lan Chen, Jinzhu Jia, Fujun Li, Yanyan Shi, Christoph Meyer, Zhongwei Zhu, Yanming Zhang, Roman Liebe, Keming Hu, Tingting Zhou, Huier Zhang, Hong-Lei Weng, Tong Huang

“…Objectives To clarify non-alcoholic fatty liver disease (NAFLD) prevalence, risk factors and clinical outcome in an exemplary Chinese population, a cohort of company employees was followed up for 11 years.Design Retrospective cohort study.Setting Between 2006 and 2016 in Ning bo, China.Participants 13 032 company employees.Results Over 11 years, the prevalence of NAFLD increased from 17.2% to 32.4% (men 20.5%–37% vs women 9.8%–22.2%). …”
Get full text

Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus by Lung-Wen Tsai, Yi-Hsiang Lu, Rajni Dubey, Jeng-Fong Chiou

“…Clinically, it has also been revealed that the existence of nonalcoholic fatty liver disease (NAFLD) enhances the incidence of type 2 diabetes mellitus (T2DM), while T2DM exacerbates NAFLD to extremely severe forms of steatohepatitis, cirrhosis, and hepatocellular carcinoma. …”
Get full text

Insulin Resistance Markers to Detect Nonalcoholic Fatty Liver Disease in a Male Hispanic Population by Maritza Pérez-Mayorga, Jose P. Lopez-Lopez, Maria A. Chacon-Manosalva, Maria G Castillo, Johanna Otero, Daniel Martinez-Bello, Diego Gomez-Arbelaez, Daniel D. Cohen, Patricio Lopez-Jaramillo

“…Background. Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver disease and is closely associated with cardiometabolic disorders, being insulin resistance (IR) the common pathogenic mechanism. …”
Get full text

The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background by Jinsheng Yu, Sharon Marsh, Junbo Hu, Wenke Feng, Chaodong Wu

“…Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and it comprises a spectrum of hepatic abnormalities from simple hepatic steatosis to steatohepatitis, fibrosis, cirrhosis, and liver cancer. …”
Get full text

Implication of Nonalcoholic Fatty Liver Disease, Metabolic Syndrome, and Subclinical Inflammation on Mild Renal Insufficiency by Ga Eun Nam, Soon Young Hwang, Hye Soo Chung, Ju Hee Choi, Hyun Jung Lee, Nam Hoon Kim, Hye Jin Yoo, Ji-A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi

“…Limited information exists about the impact of nonalcoholic fatty liver disease (NAFLD) on mild renal insufficiency. …”
Get full text

Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis by Wenxia Lu, Sainan Li, Jingjing Li, Jianrong Wang, Rong Zhang, Yuqing Zhou, Qin Yin, Yuanyuan Zheng, Fan Wang, Yujing Xia, Kan Chen, Tong Liu, Jie Lu, Yingqun Zhou, Chuanyong Guo

“…A meta-analysis was conducted to assess the effect of omega-3 fatty acid supplementation (n-3 PUFAs) in lowering liver fat, liver enzyme (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels), and blood lipids (triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL)) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). …”
Get full text

Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice by Gilles Willemin, Catherine Roger, Armelle Bauduret, Kaori Minehira

“…However, it has never been addressed whether the MHC II pathway plays an important role in the development of nonalcoholic fatty liver disease, the most common form of liver disease. …”
Get full text

The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease by T. S. Krolevets, M. A. Livzan, S. I. Mozgovoy

Subjects: Get full text

Effects of laparoscopic sleeve gastrectomy on nonalcoholic fatty liver disease and TGF-β signaling pathway by Hideki Kumagai, Akira Sasaki, Akira Umemura, Keisuke Kakisaka, Takeshi Iwaya, Satoshi S Nishizuka

Subjects: Get full text

Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease’s Statin Therapy in Men by Nikola Hadzi-Petrushev, Katerina Dimovska, Nikola Jankulovski, Dine Mitrov, Mitko Mladenov

“…Oxidative stress and inflammation contribute to the pathogenesis and progression of nonalcoholic fatty liver disease (NAFLD), and the control of lipid status by statins may help to stop the progression of NAFLD. …”
Get full text

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B by S. N. Batskikh, E. V. Vinnitskaya, E. S. Sbikina, Zh. V. Borunova, A. S. Dorofeev, Yu. G. Sandler

Subjects: Get full text

Associations between White Blood Cell Count and the Development of Incidental Nonalcoholic Fatty Liver Disease by Goh Eun Chung, Jeong Yoon Yim, Donghee Kim, Min-Sun Kwak, Jong In Yang, Su Jin Chung, Sun Young Yang, Joo Sung Kim

“…Chronic low-grade inflammation is thought to be associated with the pathogenesis of nonalcoholic fatty liver disease (NAFLD). This study aimed to determine the association between serum white blood cell (WBC) counts and the development of incidental NAFLD. …”
Get full text

Metabolic Profiles of the Gut Microbiota in Patients with Different Stages of Metabolism Dysfunction-Associated Fatty Liver Disease by X. Cao, O. Yu. Zolnikova, R. V. Maslennikov, E. A. Poluektova, E. L. Bueverova, M. S. Reshetova, M. S. Zharkova, V. T. Ivashkin

“…Aim: to study the metabolic activity of the intestinal microbiota depending on the stage of metabolic dysfunction-associated fatty liver disease (MAFLD).   Materials and methods. The study included 85 patients with MAFLD (27 patients with steatosis without steatohepatitis and fibrosis, 42 patients with steatohepatitis, 16 patients with cirrhosis as an outcome of MAFLD, Child — Pugh class A–B) and 20 healthy people who formed the control group. …”
Get full text

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions by Yong-Jik Lee, Yoo-Na Jang, Yoon-Mi Han, Hyun-Min Kim, Jong-Min Jeong, Hong Seog Seo

“…Consequently, fimasartan ameliorates nonalcoholic fatty liver disease mainly through the activation of oxidative metabolism represented by PPARδ-AMPK-PGC-1α pathway.…”
Get full text

The role of non-alcoholic fatty liver disease in the formation of atherosclerotic vascular lesions in patients with abdominal obesity by N. L. Denisov, V. B. Grinevich, Ye. V. Chernetsova, Yu. A. Kravchuk, K. V. Ivashkin

“…To study the vascular wall changes of common carotid artery and internal carotid arteries in patients with abdominal obesity (AO) and different forms of nonalcoholic fatty liver disease (NAFLD). Material and methods. The study involved 60 patients with AO (waist circumference ≥80 cm in women and ≥94 cm in men) and NAFLD who provided written informed consent to participate in the study. …”
Get full text

Marine natural products as an important source of bioactive substances for non-alcoholic fatty liver disease management by Menglei Shi, Menglei Shi, Sisi Chen, Sisi Chen, Yutong Feng, Yutong Feng, Shiyuan Wang, Yuyu Xia, Jianlin He

“…With an estimated global prevalence of 32.4%, non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent chronic liver condition. …”
Get full text